Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Currently, Enoxaparin is the usual prophylactic anticoagulant treatment at the acute and
sub-acute phases of spinal cord injury (SCI). Patients at the sub-acute phase of SCI
(rehabilitation) will be given either Enoxaparin 40 mg/day (control) or Apixaban 2.5-5 mg
twice a day. Apixaban dose will be determined by the treating physician. Treatment will be
continued for either 6 or 12 weeks following injury (for AIS grades C-D and A-B
respectively).
Endpoints: Venous thromboembolism will be evaluated by D-Dimer test every 2 weeks and an
ultrasound doppler at the end of the treatment. Bleeding events will be recorded and
hematocrit will be monitored every two weeks.